Executive Management

 

   
  Martin Olin, EMBA, M.Sc.
Chief Executive Officer
20 years of executive experience in the pharmaceutical and biotech industry. Before joining Symphogen, Mr. Olin was a senior partner with SLS Invest, a Scandinavian based healthcare focused private equity fund. Prior to joining SLS Invest Mr. Olin held managerial positions in Novo Nordisk including Finance Director, EMEA. Mr. Olin served on the board of Symphogen from 2001 – 2008 and joined as a Chief Financial Officer in 2012. Since September 2016, CEO of Symphogen. Mr. Olin is a Board member of Symphogen and also serves on the board of Ascendis Pharma (public company). Mr. Olin serves as a member of the Lifescience Growth Team appointed by the Danish Government in 2016..
   
     
Ivan D. Horak, MD, FACP
Head of Global R&D, Chief Scientific and Medical Officer
Prior to joining Symphogen in 2011, Dr. Horak served as President of Research and Development and Chief Scientific Officer of Enzon Pharmaceuticals Inc. Before that, Dr. Horak served as Chief Scientific Officer of Immunomedics, responsible for development of novel antibodies. Dr. Horak has authored over 80 peer-reviewed publications and several book chapters within the fields of hematol- ogy, oncology, and immunology and has served on the editorial boards of several scientific journals. Dr. Horak is a board-certified oncologist. He is a Fellow of the American College of Physicians and a member of the American Association for Cancer Research (AACR), the American Society of Hematology (ASH), and the American Society Clinical Oncology (ASCO).
 
     
     
Mads Laustsen, M.Sc.

Chief Manufacturing Officer
Mr. Laustsen has more than 25 years of international experience within biologics development and manufacturing from CMC Biolog- ics, Novozymes, Zymogenetics and Novo. Mr. Laustsen co-founded CMC Biologics where he was the Chief Executive Officer and Chief Science Officer prior to joining Symphogen. Until March 1, 2017 Mr. Laustsen was a board member of CMC Biologics. Furthermore, he holds numerous patents related to biologics manufacturing and is on the Advisory Board of Institute of System Biology at the Danish Technical University..

 
     
     
Jesper Bramming, M.Sc. Economics

Chief Financial Officer
Joining Symphogen in 2016, Mr. Bramming came from the CMC Biologics group where he was Chief Financial Officer and a member of the group Management Team. Before joining CMC Biologics, Mr. Bramming was Chief Financial Officer at Nets Holding A/S. Prior to that, he held positions in the A.P. Moller – Maersk group – in group Finance and as CFO of Maersk Oil & Gas and Svitzer. Prior to these assignments, Bramming held a number of top positions in banking and investment management in leading European firms. He holds Board seats as Chairman of Rejsekort A/S, and as director of Danske Invest Management. He holds a Master of Economics from the University of Copenhagen, and is an alumni of Columbia University's Senior Executive Management Program and is CFA charter holder..